Sally C. Pipes

Commentary

New COVID-19 research is troubling

Gov’t Undermines Search for Heart Disease Treatments

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread ...
Commentary

Moderna, Pfizer signal they plan to raise price of their shots

In defense of pandemic profits

The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Commentary

Read the most recent update on the COVID public health emergency

Why is Medicaid still treating COVID-19 as a public health emergency?

The federal public health emergency for the COVID-19 pandemic came to an end Thursday, more than three years after it was first enacted in 2020. That comes on the heels of the World Health Organization’s declaration on May 5 that COVID-19 was no longer a global health emergency. And on ...
Commentary

Medicaid Work Requirements Address Laziness Head On

The spending cuts included in the bill House Republicans passed in late April to raise the debt ceiling have Democrats up in arms. But federal spending has soared. It’s now 5 percentage points higher as a share of GDP than the average since 1960. As House Speaker Kevin McCarthy quipped this week, “Is it ...
Commentary

Today's commentary on pharmaceutical benefit managers

Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?

Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — ...
Commentary

Thank the IRA for Cuts to Critical Drug Research

President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 ...
Commentary

Small-Molecule Price Controls Are A Big Mistake

The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Commentary

Read about Biden's latest policy proposal

Time for Hospitals to Come Clean About Pricing

The Biden administration is cracking down on hospitals that keep their prices secret. Under a policy announced last week, failing to abide by Trump-era hospital price transparency rules will no longer prompt a warning letter from the Centers for Medicare and Medicaid Services. Instead, hospitals will have 45 days to ...
Commentary

Biden wants to add another few billion dollars to the deficit

Don’t expand Medicaid to noncitizens

Last week, the Biden administration released a plan that would open up Medicaid and Obamacare to nearly 580,000 undocumented immigrants. Never mind that the federal deficit is projected to reach $1.4 trillion this year. What’s another few billion dollars? The proposed rule centers around the Deferred Action for Childhood Arrivals program, which allows undocumented ...
Commentary

Golden State Teeters on Edge of Healthcare Cliff

Democrats in the California Legislature are moving ahead with a new bid to impose single-payer health care in the Golden State. Last week, the Senate Health Committee green-lit SB 770 by a 7-2 margin. The measure holds Gov. Gavin Newsom to a set of deadlines for advancing his long-promised government takeover of ...
Commentary

New COVID-19 research is troubling

Gov’t Undermines Search for Heart Disease Treatments

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread ...
Commentary

Moderna, Pfizer signal they plan to raise price of their shots

In defense of pandemic profits

The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Commentary

Read the most recent update on the COVID public health emergency

Why is Medicaid still treating COVID-19 as a public health emergency?

The federal public health emergency for the COVID-19 pandemic came to an end Thursday, more than three years after it was first enacted in 2020. That comes on the heels of the World Health Organization’s declaration on May 5 that COVID-19 was no longer a global health emergency. And on ...
Commentary

Medicaid Work Requirements Address Laziness Head On

The spending cuts included in the bill House Republicans passed in late April to raise the debt ceiling have Democrats up in arms. But federal spending has soared. It’s now 5 percentage points higher as a share of GDP than the average since 1960. As House Speaker Kevin McCarthy quipped this week, “Is it ...
Commentary

Today's commentary on pharmaceutical benefit managers

Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?

Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — ...
Commentary

Thank the IRA for Cuts to Critical Drug Research

President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 ...
Commentary

Small-Molecule Price Controls Are A Big Mistake

The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly ...
Commentary

Read about Biden's latest policy proposal

Time for Hospitals to Come Clean About Pricing

The Biden administration is cracking down on hospitals that keep their prices secret. Under a policy announced last week, failing to abide by Trump-era hospital price transparency rules will no longer prompt a warning letter from the Centers for Medicare and Medicaid Services. Instead, hospitals will have 45 days to ...
Commentary

Biden wants to add another few billion dollars to the deficit

Don’t expand Medicaid to noncitizens

Last week, the Biden administration released a plan that would open up Medicaid and Obamacare to nearly 580,000 undocumented immigrants. Never mind that the federal deficit is projected to reach $1.4 trillion this year. What’s another few billion dollars? The proposed rule centers around the Deferred Action for Childhood Arrivals program, which allows undocumented ...
Commentary

Golden State Teeters on Edge of Healthcare Cliff

Democrats in the California Legislature are moving ahead with a new bid to impose single-payer health care in the Golden State. Last week, the Senate Health Committee green-lit SB 770 by a 7-2 margin. The measure holds Gov. Gavin Newsom to a set of deadlines for advancing his long-promised government takeover of ...
Scroll to Top